Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Moon

Showing results (571-580 of 876) with videos related to

Pageof 88
Sort By:
Oncogene|May 31, 2016
Foxp3 is a key downstream regulator of p53-mediated cellular senescenceJ-E Kim, J-S Shin, J-H Moon, et al.
Leukemia|January 17, 2017
The clonal origins of leukemic progression of myelodysplasiaT Kim, M S Tyndel, H J Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2010
Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patientsM K Kim, C Suh, D H Lee, et al.
Cell Death and Differentiation|October 22, 2013
p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTENS-W Hong, J-H Moon, J-S Kim, et al.
Journal of the National Cancer Institute|November 21, 2019
PIK3CA Mutation in HPV-Associated OPSCC Patients Receiving Deintensified ChemoradiationBrian T Beaty, Dominic H Moon, Colette J Shen, et al.
Oncogene|June 6, 2012
SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatmentS-W Hong, S-H Lee, J-H Moon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Physical Review Letters|November 20, 2020
Search for Sub-eV Sterile Neutrinos at RENOJ H Choi, H I Jang, J S Jang, et al.
International Journal of Impotence Research|October 29, 2000
Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in KoreaS C Kim, T Y Ahn, H K Choi, et al.
Pageof 88

Showing results (571-580 of 876) with videos related to

Sort By:
Pageof 88
Oncogene|May 31, 2016
Foxp3 is a key downstream regulator of p53-mediated cellular senescenceJ-E Kim, J-S Shin, J-H Moon, et al.
Leukemia|January 17, 2017
The clonal origins of leukemic progression of myelodysplasiaT Kim, M S Tyndel, H J Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2010
Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patientsM K Kim, C Suh, D H Lee, et al.
Cell Death and Differentiation|October 22, 2013
p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTENS-W Hong, J-H Moon, J-S Kim, et al.
Journal of the National Cancer Institute|November 21, 2019
PIK3CA Mutation in HPV-Associated OPSCC Patients Receiving Deintensified ChemoradiationBrian T Beaty, Dominic H Moon, Colette J Shen, et al.
Oncogene|June 6, 2012
SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatmentS-W Hong, S-H Lee, J-H Moon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Physical Review Letters|November 20, 2020
Search for Sub-eV Sterile Neutrinos at RENOJ H Choi, H I Jang, J S Jang, et al.
International Journal of Impotence Research|October 29, 2000
Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in KoreaS C Kim, T Y Ahn, H K Choi, et al.
Pageof 88